Skip to main content
. 2017 Jun 20;158(9):2722–2740. doi: 10.1210/en.2017-00355

Figure 6.

Figure 6.

(a–c) Bone marrow osterix+ cells and (d–f) flow cytometry analysis of the means of the frequency of femoral bone marrow CD45−/CD105+/CD146+/CD105+/nestin+ cells in ovariectomized WT and Nmp4−/− mice (24 weeks of age). (b and e) We compared the anabolic therapies PTH + RAL, PTH + ZOL, and PTH with each other and with VEH using either osterix+ expression or the expression profile of CD45−/CD105+/CD146+/CD105+/nestin+ as the endpoints. (c) We compared the number of osterix+ cells in the WT and Nmp4−/− RAL monotherapy cohorts. (f) We compared the anticatabolic treatments ZOL and RAL with each other and with VEH using the expression profile of CD45−/CD105+/CD146+/CD105+/nestin+ as the endpoint. Statistical analyses were performed using two-way analyses of variance, setting genotype and treatment as the independent variables. Statistical significance was set at P ≤ 0.05. The asterisk denotes genotype × treatment interaction. The data represent mean ± standard deviation, n = 4 to 6 osterix+ cells and n = 7 to 12 mice per group for flow cytometry. See text for explanation of results.